Thermalin
Cleveland
About Thermalin
Thermalin hopes to disrupt the $30B insulin/insulin delivery market with a disposable, postage-stamp-sized glucose management system enabled by our first-in-class stabilized, highly concentrated, and ultra-rapid acting insulin. This same new insulin molecule in "ordinary" (U-100) concentration will enable the factory-filling of reservoirs for existing insulin pumps. In addition to this lead program, Thermalin is developing partnerships on no-cold-chain basal and mix insulins and on glucose-responsive insulins.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Private
- Employees: 11 – 50
- Estimated revenue: Less than $1M
- Total funding: $37.6M
- Last round: Series Unknown (Aug 2022)
- Website: thermalin.com
- Phone: 617-695-0523
Industries & Categories
Biotechnology, Health Care, Life Science, Medical
Social Profiles
Canonical: https://fsome.com/organization/thermalin-38150 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.